Cole, Jones and Todd: early clinical appraisal of ICI 46,474 in breast cancer

What changed

An anti-oestrogenic candidate showed a reported response signal in late/recurrent breast cancer patients.

Scientific scope

1971 early clinical appraisal only; randomized efficacy, adjuvant treatment, survival and long-term safety excluded.

Evidence

The linked sources identify this contribution and its scope. WRS has not independently reconstructed the scientific claims. This is an early uncontrolled clinical appraisal, not proof of comparative efficacy, adjuvant benefit or long-term safety. Later randomized trials and the drug’s broader development require separate records and attribution.

Contributors

• M. P. Cole · SCIENCE: Named source author of the scoped work; individual effort shares are not measured.
• C. T. A. Jones · SCIENCE: Named source author of the scoped work; individual effort shares are not measured.
• I. D. H. Todd · SCIENCE: Named source author of the scoped work; individual effort shares are not measured.

• Cole, Jones and Todd, early clinical appraisal of ICI 46,474
• Cole, Jones and Todd, A New Anti-oestrogenic Agent in Late Breast Cancer

Provisional WRS assessment, edition 2026-10-16.1. Independent expert calibration is pending. This grade does not certify correctness or assign ownership.

Full scientific record · Browse contribution grades · Request a correction